Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Influenza

Free Subscription Articles published in Arch Virol Retrieve available abstracts of 127 articles: HTML format

Single Articles

September 2023
1. DAVE B, Shah KC, Chorawala MR, Shah N, et al
   Molnupiravir: an antiviral drug against COVID-19.
   Arch Virol. 2023;168:252.
   PubMed     Abstract available
   
   
   
2. DEGIUSEPPE JI, Martelli A, Barrios Mathieur C, Stupka JA, et al
   Genetic diversity of rotavirus A in Argentina during 2019-2022: detection of G6 strains and insights regarding its dissemination.
   Arch Virol. 2023;168:251.
   PubMed     Abstract available
   
   
   August 2023
3. TRIPATHY AS, Wagh P, Akolkar K, Walimbe AM, et al
   Association of inhibitory NKG2A and activating NKG2D natural killer cell receptor genes with resistance to SARS-CoV-2 infection in a western Indian population.
   Arch Virol. 2023;168:237.
   PubMed     Abstract available
   
   
   
4. PHAM NTK, Khamrin P, Shimizu-Onda Y, Hoque SA, et al
   Genetic diversity and declining norovirus prevalence in infants and children during Japan's COVID-19 pandemic: a three-year molecular surveillance.
   Arch Virol. 2023;168:231.
   PubMed     Abstract available
   
   
   
5. ZHOU Y, Chen Z
   Mpox: a review of laboratory detection techniques.
   Arch Virol. 2023;168:221.
   PubMed     Abstract available
   
   
   July 2023
6. MA H, Ren S, Meng Q, Su B, et al
   Role of Tim-3 in COVID-19: a potential biomarker and therapeutic target.
   Arch Virol. 2023;168:213.
   PubMed     Abstract available
   
   
   June 2023
7. FAYYAD-KAZAN M, Makki R, Homsi ME, Samadi A, et al
   Circulating microRNA profile in response to remdesivir treatment in coronavirus disease 2019 (COVID-19) patients.
   Arch Virol. 2023;168:194.
   PubMed     Abstract available
   
   
   
8. LOBAINA Y, Chen R, Suzarte E, Ai P, et al
   Broad humoral immunity generated in mice by a formulation composed of two antigens from the Delta variant of SARS-CoV-2.
   Arch Virol. 2023;168:190.
   PubMed     Abstract available
   
   
   
9. BHANOTHU V, Munne K, Pande S, Singh P, et al
   The dynamics of SARS-CoV-2 infection in unvaccinated and vaccinated populations in Mumbai, India, between 28 December 2020 and 30 August 2021.
   Arch Virol. 2023;168:188.
   PubMed     Abstract available
   
   
   
10. SENTHILAZHAGAN K, Sakthimani S, Kallanja D, Venkataraman S, et al
    SARS-CoV-2: analysis of the effects of mutations in non-structural proteins.
    Arch Virol. 2023;168:186.
    PubMed     Abstract available
    
    
    
11. UPADHYAY R, Tiwari KN
    The antiviral potential of Phyllanthus species: a systematic review.
    Arch Virol. 2023;168:177.
    PubMed     Abstract available
    
    
    
12. VALDES-LOPEZ JF, Urcuqui-Inchima S
    Antiviral response and immunopathogenesis of interleukin 27 in COVID-19.
    Arch Virol. 2023;168:178.
    PubMed     Abstract available
    
    
    
13. PATTANAIK A, Bhandarkar B S, Lodha L, Marate S, et al
    SARS-CoV-2 and the nervous system: current perspectives.
    Arch Virol. 2023;168:171.
    PubMed     Abstract available
    
    
    May 2023
14. ZHANG Y, Wang J, Xie Y, Cao X, et al
    Epidemiological characteristics of patients from fever clinics during the COVID-19 epidemic in 2022 in Shanghai, China.
    Arch Virol. 2023;168:164.
    PubMed     Abstract available
    
    
    
15. SUHARSONO H, Mahardika BK, Sudipa PH, Sari TK, et al
    Consensus insertion/deletions and amino acid variations of all coding and noncoding regions of the SARS-CoV-2 Omicron clades, including the XBB and BQ.1 lineages.
    Arch Virol. 2023;168:156.
    PubMed     Abstract available
    
    
    
16. TATSI EB, Koukou DM, Dellis C, Dourdouna MM, et al
    Epidemiological study of unusual rotavirus strains and molecular characterization of emerging P[14] strains isolated from children with acute gastroenteritis during a 15-year period.
    Arch Virol. 2023;168:149.
    PubMed     Abstract available
    
    
    April 2023
17. MANSOURABADI AH, Aghamajidi A, Dorfaki M, Keshavarz F, et al
    B lymphocytes in COVID-19: a tale of harmony and discordance.
    Arch Virol. 2023;168:148.
    PubMed     Abstract available
    
    
    
18. DA COSTA MA, de Almeida RPA, Ponde RAA
    Clinical-laboratory profile of children and adolescents with multisystem inflammatory syndrome temporarily associated with COVID-19 in Goias, Brazil.
    Arch Virol. 2023;168:142.
    PubMed     Abstract available
    
    
    
19. KAWABATA K, Sato Y, Kubo T, Tokumura A, et al
    Phospholipid analysis of two influenza A virus-infected cell lines differing in their viral replication kinetics.
    Arch Virol. 2023;168:132.
    PubMed     Abstract available
    
    
    March 2023
20. MARTINS M, do Nascimento GM, Conforti A, Noll JCG, et al
    A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets.
    Arch Virol. 2023;168:124.
    PubMed     Abstract available
    
    
    
21. MAO L, Chen Y, Gu J, Zhao Y, et al
    Roles and mechanisms of exosomal microRNAs in viral infections.
    Arch Virol. 2023;168:121.
    PubMed     Abstract available
    
    
    
22. SHI T, Zhao X, Zhang X, Meng L, et al
    Immediate and long-term changes in the epidemiology, infection spectrum, and clinical characteristics of viral and bacterial respiratory infections in Western China after the COVID-19 outbreak: a modeling study.
    Arch Virol. 2023;168:120.
    PubMed     Abstract available
    
    
    
23. ZABIHI RIZI F, Ghorbani A, Zahtab P, Darbaghshahi NN, et al
    TYK2 single-nucleotide variants associated with the severity of COVID-19 disease.
    Arch Virol. 2023;168:119.
    PubMed     Abstract available
    
    
    
24. BORKAKOTI R, Karikalan M, Nehul SK, Jogi HR, et al
    A retrospective study showing a high rate of seropositivity against SARS-CoV-2 in wild felines in India.
    Arch Virol. 2023;168:109.
    PubMed     Abstract available
    
    
    February 2023
25. FALCON-CAMA V, Montero-Gonzalez T, Acosta-Medina EF, Guillen-Nieto G, et al
    Evidence of SARS-CoV-2 infection in postmortem lung, kidney, and liver samples, revealing cellular targets involved in COVID-19 pathogenesis.
    Arch Virol. 2023;168:96.
    PubMed     Abstract available
    
    
    
26. SALEM S, Mosaad R, Lotfy R, Elbadry M, et al
    Altered expression of DNA methyltransferases and methylation status of the TLR4 and TNF-alpha promoters in COVID-19.
    Arch Virol. 2023;168:95.
    PubMed     Abstract available
    
    
    
27. NEMOTO M, Reedy SE, Yano T, Suzuki K, et al
    Antigenic comparison of H3N8 equine influenza viruses belonging to Florida sublineage clade 1 between vaccine strains and North American strains isolated in 2021-2022.
    Arch Virol. 2023;168:94.
    PubMed     Abstract available
    
    
    
28. QUISPE-RICALDE MA, Castelan-Sanchez HG, Meza-Rodriguez PM, Davila-Ramos S, et al
    Evidence of natural selection and dominance of SARS-CoV-2 variant Lambda (C.37) over variants of concern in Cusco, Peru.
    Arch Virol. 2023;168:88.
    PubMed     Abstract available
    
    
    
29. RAMOS N, Panzera Y, Frabasile S, Tomas G, et al
    A multiplex-NGS approach to identifying respiratory RNA viruses during the COVID-19 pandemic.
    Arch Virol. 2023;168:87.
    PubMed     Abstract available
    
    
    
30. KAYED AE, Kutkat O, Kandeil A, Moatasim Y, et al
    Comparative pathogenic potential of avian influenza H7N3 viruses isolated from wild birds in Egypt and their sensitivity to commercial antiviral drugs.
    Arch Virol. 2023;168:82.
    PubMed     Abstract available
    
    
    January 2023
31. KHARROUBI G, Cherif I, Ghawar W, Dhaouadi N, et al
    Incidence and risk factors of SARS-CoV-2 infection among workers in a public health laboratory in Tunisia.
    Arch Virol. 2023;168:69.
    PubMed     Abstract available
    
    
    
32. PANAGIOTIDIS GD, Muller C, Binder M, Weber F, et al
    Influenza A virus strain PR/8/34, but neither HAM/2009 nor WSN/33, is transiently inhibited by the PB2-targeting drug paliperidone.
    Arch Virol. 2023;168:63.
    PubMed     Abstract available
    
    
    
33. FENG Z, Xu B, Zhong L, Chen J, et al
    A multicentre study on the incidence of respiratory viruses in children with community-acquired pneumonia requiring hospitalization in the setting of the zero-COVID policy in China.
    Arch Virol. 2023;168:64.
    PubMed     Abstract available
    
    
    
34. MITARAI S, Okuya K, Miyane K, Miyamoto M, et al
    Genetic characterization of bovine respiratory syncytial viruses in Japan between 2017 and 2019.
    Arch Virol. 2023;168:51.
    PubMed     Abstract available
    
    
    
35. REZAEE D, Bakhtiari S, Jalilian FA, Doosti-Irani A, et al
    Coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus during the COVID-19 pandemic.
    Arch Virol. 2023;168:53.
    PubMed     Abstract available
    
    
    
36. PUENPA J, Rattanakomol P, Saengdao N, Chansaenroj J, et al
    Molecular characterisation and tracking of severe acute respiratory syndrome coronavirus 2 in Thailand, 2020-2022.
    Arch Virol. 2023;168:26.
    PubMed     Abstract available
    
    
    
37. VARELA APM, Sant'Anna FH, Dos Santos AV, Prichula J, et al
    Genomic evidence of SARS-CoV-2 reinfection cases in southern Brazil.
    Arch Virol. 2023;168:19.
    PubMed     Abstract available
    
    
    December 2022
38. NIU X, Xu J, Liu M, Tu H, et al
    Isolation and characterization of a SARS-CoV-2 variant with a Q677H mutation in the spike protein.
    Arch Virol. 2022;168:5.
    PubMed     Abstract available
    
    
    
39. FRAZZINI S, Amadori M, Turin L, Riva F, et al
    SARS CoV-2 infections in animals, two years into the pandemic.
    Arch Virol. 2022;167:2503-2517.
    PubMed     Abstract available
    
    
    
40. FU Y, Huang Y, Rao J, Zeng F, et al
    Host adaptation of codon usage in SARS-CoV-2 from mammals indicates potential natural selection and viral fitness.
    Arch Virol. 2022;167:2677-2688.
    PubMed     Abstract available
    
    
    November 2022
41. GRACHEVA AV, Korchevaya ER, Ammour YI, Smirnova DI, et al
    Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light.
    Arch Virol. 2022;167:2181-2191.
    PubMed     Abstract available
    
    
    
42. DE OLIVEIRA CM, Romano CM, Sussuchi L, Cota BDCV, et al
    SARS-CoV-2 BA.1 and BA.2 coinfection detected by genomic surveillance in Brazil, January 2022.
    Arch Virol. 2022;167:2271-2273.
    PubMed     Abstract available
    
    
    October 2022
43. DABAJA-YOUNIS H, Fuchs E, Shorbaji N, Appel T, et al
    SARS-CoV-2 and seasonal influenza: similarities and disparities.
    Arch Virol. 2022 Oct 21. pii: 10.1007/s00705-022-05615.
    PubMed     Abstract available
    
    
    
44. KARIMIAN A, Behjati M, Karimian M
    Molecular mechanisms involved in anosmia induced by SARS-CoV-2, with a focus on the transmembrane serine protease TMPRSS2.
    Arch Virol. 2022;167:1931-1946.
    PubMed     Abstract available
    
    
    
45. YELEMALI P, Hao L, Liu Q
    Mechanisms of host type I interferon response modulation by the nucleocapsid proteins of alpha- and betacoronaviruses.
    Arch Virol. 2022;167:1925-1930.
    PubMed     Abstract available
    
    
    September 2022
46. LI ZX, Feng S, Zhang H, Zhuang XY, et al
    Immunogenicity and protective efficacy of a DNA vaccine inducing optimal expression of the SARS-CoV-2 S gene in hACE2 mice.
    Arch Virol. 2022 Sep 9. pii: 10.1007/s00705-022-05562.
    PubMed     Abstract available
    
    
    August 2022
47. YANG F, Zhang X, Liu F, Yao H, et al
    Rapid emergence of a PB2 D701N substitution during adaptation of an H9N2 avian influenza virus in mice.
    Arch Virol. 2022 Aug 3. pii: 10.1007/s00705-022-05536.
    PubMed     Abstract available
    
    
    
48. NAGY A, Stara M, Vodicka R, Cernikova L, et al
    Reverse-zoonotic transmission of SARS-CoV-2 lineage alpha (B.1.1.7) to great apes and exotic felids in a zoo in the Czech Republic.
    Arch Virol. 2022;167:1681-1685.
    PubMed     Abstract available
    
    
    July 2022
49. NGWE TUN MM, Luvai E, Nwe KM, Toume K, et al
    Anti-SARS-CoV-2 activity of various PET-bottled Japanese green teas and tea compounds in vitro.
    Arch Virol. 2022;167:1547-1557.
    PubMed     Abstract available
    
    
    
50. BAHLAWAN O, Badra R, Semaan H, Fayad N, et al
    Prevalence and determinants of SARS-CoV-2 neutralizing antibodies in Lebanon.
    Arch Virol. 2022;167:1509-1519.
    PubMed     Abstract available
    
    
    June 2022
51. DAHER-NASHIF S, Al-Anany R, Ali M, Erradi K, et al
    COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity.
    Arch Virol. 2022 Jun 20. pii: 10.1007/s00705-022-05495.
    PubMed     Abstract available
    
    
    May 2022
52. TAKIZAWA N, Momose F
    A novel E198K substitution in the PA gene of influenza A virus with reduced susceptibility to baloxavir acid.
    Arch Virol. 2022 May 5. pii: 10.1007/s00705-022-05456.
    PubMed     Abstract available
    
    
    
53. PIERI M, Nicolai E, Nuccetelli M, Sarubbi S, et al
    Validation of a quantitative lateral flow immunoassay (LFIA)-based point-of-care (POC) rapid test for SARS-CoV-2 neutralizing antibodies.
    Arch Virol. 2022;167:1285-1291.
    PubMed     Abstract available
    
    
    April 2022
54. NAGY A, Cernikova L, Stara M
    A new clade 2.3.4.4b H5N1 highly pathogenic avian influenza genotype detected in Europe in 2021.
    Arch Virol. 2022 Apr 26. pii: 10.1007/s00705-022-05442.
    PubMed     Abstract available
    
    
    
55. JIANG H, Yang T, Yang C, Lu Y, et al
    Molecular epidemiology and clinical characterization of human rhinoviruses circulating in Shanghai, 2012-2020.
    Arch Virol. 2022;167:1111-1123.
    PubMed     Abstract available
    
    
    
56. MWANGI P, Mogotsi M, Ogunbayo A, Mooko T, et al
    A decontamination strategy for resolving SARS-CoV-2 amplicon contamination in a next-generation sequencing laboratory.
    Arch Virol. 2022;167:1175-1179.
    PubMed     Abstract available
    
    
    
57. ALEJO-CANCHO I, Gual-de-Torrella A, Gallego M, Urrutikoetxea-Gutierrez M, et al
    Misidentification of the SARS-CoV-2 Mu variant using commercial mutation screening assays.
    Arch Virol. 2022;167:1141-1144.
    PubMed     Abstract available
    
    
    
58. ATIYA-NASAGI Y, Milrot E, Makdasi E, Schuster O, et al
    Development of an immunofluorescence assay for detection of SARS-CoV-2.
    Arch Virol. 2022;167:1041-1049.
    PubMed     Abstract available
    
    
    
59. COLSON P, Delerce J, Burel E, Dahan J, et al
    Emergence in southern France of a new SARS-CoV-2 variant harbouring both N501Y and E484K substitutions in the spike protein.
    Arch Virol. 2022;167:1185-1190.
    PubMed     Abstract available
    
    
    
60. WANG Y, Li P, Lavrijsen M, Li Y, et al
    Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions.
    Arch Virol. 2022;167:1125-1130.
    PubMed     Abstract available
    
    
    March 2022
61. DA SILVA MS, Mosena ACS, Baumbach L, Demoliner M, et al
    Cattle influenza D virus in Brazil is divergent from established lineages.
    Arch Virol. 2022 Mar 17. pii: 10.1007/s00705-022-05416.
    PubMed     Abstract available
    
    
    
62. BEHESHTIROUY S, Khani E, Khiali S, Entezari-Maleki T, et al
    Investigational antiviral drugs for the treatment of COVID-19 patients.
    Arch Virol. 2022;167:751-805.
    PubMed     Abstract available
    
    
    
63. LE TB, Kim HK, Ahn MJ, Zanin M, et al
    Diagnostic performance and clinical feasibility of a novel one-step RT-qPCR assay for simultaneous detection of multiple severe acute respiratory syndrome coronaviruses.
    Arch Virol. 2022;167:871-879.
    PubMed     Abstract available
    
    
    
64. KLOC M, Uosef A, Wosik J, Kubiak JZ, et al
    Virus interactions with the actin cytoskeleton-what we know and do not know about SARS-CoV-2.
    Arch Virol. 2022;167:737-749.
    PubMed     Abstract available
    
    
    February 2022
65. SALEHI-VAZIRI M, Fazlalipour M, Seyed Khorrami SM, Azadmanesh K, et al
    The ins and outs of SARS-CoV-2 variants of concern (VOCs).
    Arch Virol. 2022;167:327-344.
    PubMed     Abstract available
    
    
    
66. COLSON P, Fantini J, Yahi N, Delerce J, et al
    Limited spread of a rare spike E484K-harboring SARS-CoV-2 in Marseille, France.
    Arch Virol. 2022;167:583-589.
    PubMed     Abstract available
    
    
    
67. WANG HX, Zhang L, Liang ZT, Nie JH, et al
    Infectivity and antigenicity of pseudoviruses with high-frequency mutations of SARS-CoV-2 identified in Portugal.
    Arch Virol. 2022;167:459-470.
    PubMed     Abstract available
    
    
    
68. KIM Y, Jang G, Lee D, Kim N, et al
    Trypsin enhances SARS-CoV-2 infection by facilitating viral entry.
    Arch Virol. 2022;167:441-458.
    PubMed     Abstract available
    
    
    
69. ZHANG L, Guo X, Jiang H, Zhao N, et al
    Decreased incidence of acute hemorrhagic conjunctivitis associated with enhanced public health intervention during the COVID-19 epidemic in China, 2020.
    Arch Virol. 2022;167:577-581.
    PubMed     Abstract available
    
    
    
70. SHRIVASTAVA S, Mhaske ST, Modak MS, Virkar RG, et al
    Emergence of two distinct variants of SARS-CoV-2 and an explosive second wave of COVID-19: the experience of a tertiary care hospital in Pune, India.
    Arch Virol. 2022;167:393-403.
    PubMed     Abstract available
    
    
    
71. SAFARI I, Elahi E
    Evolution of the SARS-CoV-2 genome and emergence of variants of concern.
    Arch Virol. 2022;167:293-305.
    PubMed     Abstract available
    
    
    January 2022
72. FUMAGALLI MJ, Capato CF, de Castro-Jorge LA, de Souza WM, et al
    Stability of SARS-CoV-2 and other airborne viruses under different stress conditions.
    Arch Virol. 2022;167:183-187.
    PubMed     Abstract available
    
    
    December 2021
73. BUITRAGO SP, Garzon-Ospina D
    Genetic diversity of SARS-CoV-2 in South America: demographic history and structuration signals.
    Arch Virol. 2021;166:3357-3371.
    PubMed     Abstract available
    
    
    
74. TRIPATHY AS, Vishwakarma S, Trimbake D, Gurav YK, et al
    Pro-inflammatory CXCL-10, TNF-alpha, IL-1beta, and IL-6: biomarkers of SARS-CoV-2 infection.
    Arch Virol. 2021;166:3301-3310.
    PubMed     Abstract available
    
    
    
75. SHI B, Song Q, Luo X, Song J, et al
    Identification of cryptic putative IRESs within the ORF encoding the nonstructural proteins of the human rhinovirus 16 genome.
    Arch Virol. 2021;166:3373-3386.
    PubMed     Abstract available
    
    
    November 2021
76. VIJAYAKUMAR P, Raut AA, Chingtham S, Murugkar HV, et al
    Proteomic analysis of differential expression of lung proteins in response to highly pathogenic avian influenza virus infection in chickens.
    Arch Virol. 2021 Nov 16. pii: 10.1007/s00705-021-05287.
    PubMed     Abstract available
    
    
    
77. TSUNEKI-TOKUNAGA A, Kondo T, Kanai K, Itagaki A, et al
    Local spread of influenza A (H1N1) viruses without a mutation for the maximum duration of an epidemic season in Japan.
    Arch Virol. 2021 Nov 11. pii: 10.1007/s00705-021-05301.
    PubMed     Abstract available
    
    
    
78. WANG S, Liu Y, Yu L, Liang T, et al
    A strain of highly pathogenic porcine reproductive and respiratory syndrome virus: genomic characterization, pathogenicity, and construction of an infectious full-length cDNA clone.
    Arch Virol. 2021;166:3127-3141.
    PubMed     Abstract available
    
    
    
79. RASTEGAR M, Samadizadeh S, Yasaghi M, Moradi A, et al
    Functional variation (Q63R) in the cannabinoid CB2 receptor may affect the severity of COVID-19: a human study and molecular docking.
    Arch Virol. 2021;166:3117-3126.
    PubMed     Abstract available
    
    
    
80. DU X, Wu G, Zhu Y, Zhang S, et al
    Exploring the epidemiological changes of common respiratory viruses since the COVID-19 pandemic: a hospital study in Hangzhou, China.
    Arch Virol. 2021;166:3085-3092.
    PubMed     Abstract available
    
    
    
81. RODRIGUEZ-MALDONADO AP, Vazquez-Perez JA, Cedro-Tanda A, Taboada B, et al
    Emergence and spread of the potential variant of interest (VOI) B.1.1.519 of SARS-CoV-2 predominantly present in Mexico.
    Arch Virol. 2021;166:3173-3177.
    PubMed     Abstract available
    
    
    October 2021
82. JANG Y, Seo SH
    H5 cleavage-site peptide vaccine protects chickens from lethal infection by highly pathogenic H5 avian influenza viruses.
    Arch Virol. 2021 Oct 25. pii: 10.1007/s00705-021-05284.
    PubMed     Abstract available
    
    
    
83. DOMNICH A, De Pace V, Pennati BM, Caligiuri P, et al
    Evaluation of extraction-free RT-qPCR methods for SARS-CoV-2 diagnostics.
    Arch Virol. 2021;166:2825-2828.
    PubMed     Abstract available
    
    
    
84. HU J, Stojanovic J, Yasamineh S, Yasamineh P, et al
    The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection.
    Arch Virol. 2021;166:2649-2672.
    PubMed     Abstract available
    
    
    September 2021
85. SUN Y, Mao H, Lou X, Wang X, et al
    Molecular epidemiologic characteristics of hemagglutinin from five waves of avian influenza A (H7N9) virus infection, from 2013 to 2017, in Zhejiang Province, China.
    Arch Virol. 2021 Sep 30. pii: 10.1007/s00705-021-05233.
    PubMed     Abstract available
    
    
    
86. LAVERACK M, Tallmadge RL, Venugopalan R, Cronk B, et al
    Clinical evaluation of a multiplex real-time RT-PCR assay for detection of SARS-CoV-2 in individual and pooled upper respiratory tract samples.
    Arch Virol. 2021;166:2551-2561.
    PubMed     Abstract available
    
    
    
87. NAGY A, Basiouni S, Parvin R, Hafez HM, et al
    Evolutionary insights into the furin cleavage sites of SARS-CoV-2 variants from humans and animals.
    Arch Virol. 2021;166:2541-2549.
    PubMed     Abstract available
    
    
    
88. MARCHIO A, Batejat C, Vanhomwegen J, Feher M, et al
    ddPCR increases detection of SARS-CoV-2 RNA in patients with low viral loads.
    Arch Virol. 2021;166:2529-2540.
    PubMed     Abstract available
    
    
    
89. ABDELWAHAB SF, Mohamed MK, Ali WY, Ali AS, et al
    Role of polymeric materials in preventing COVID-19 infection.
    Arch Virol. 2021;166:2487-2493.
    PubMed     Abstract available
    
    
    
90. BOONARKART C, Suptawiwat O, Ruangrung K, Maneechotesuwan K, et al
    Microparticles from human the lower airway show inhibitory activity against respiratory syncytial virus.
    Arch Virol. 2021;166:2579-2584.
    PubMed     Abstract available
    
    
    
91. MA Y, Jiang H, Wan Z, Li S, et al
    Evolutionary dynamics of group A and B respiratory syncytial virus in China, 2009-2018.
    Arch Virol. 2021;166:2407-2418.
    PubMed     Abstract available
    
    
    August 2021
92. PENG J, Liu ZY, Yu XJ, Chen XY, et al
    Antibody response in COVID-19 patients with and without re-positive RT-PCR results during the convalescent phase.
    Arch Virol. 2021;166:2299-2303.
    PubMed     Abstract available
    
    
    
93. SHABBIR S, Raza MH, Arshad M, Khan MJ, et al
    The interplay between the immune system and SARS-CoV-2 in COVID-19 patients.
    Arch Virol. 2021;166:2109-2117.
    PubMed     Abstract available
    
    
    
94. HASHEMI SMA, Thijssen M, Hosseini SY, Tabarraei A, et al
    Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection.
    Arch Virol. 2021;166:2089-2108.
    PubMed     Abstract available
    
    
    
95. ZHANG L, Hou J, Ma FZ, Li J, et al
    The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis.
    Arch Virol. 2021;166:2071-2087.
    PubMed     Abstract available
    
    
    July 2021
96. ZHOU S, Mao N, Zhang Y, Cui A, et al
    Genetic analysis of human parainfluenza virus type 4 associated with severe acute respiratory infection in children in Luohe City, Henan Province, China, during 2017-2018.
    Arch Virol. 2021 Jul 6. pii: 10.1007/s00705-021-05154.
    PubMed     Abstract available
    
    
    
97. YUAN HW, Wen HL
    Research progress on coronavirus S proteins and their receptors.
    Arch Virol. 2021;166:1811-1817.
    PubMed     Abstract available
    
    
    
98. MIRZAEI R, Attar A, Papizadeh S, Jeda AS, et al
    The emerging role of probiotics as a mitigation strategy against coronavirus disease 2019 (COVID-19).
    Arch Virol. 2021;166:1819-1840.
    PubMed     Abstract available
    
    
    June 2021
99. ZENG MS, Yu WD, Wang HX, Xu PP, et al
    Puerarin reduces impairment of intestinal and adipose immune responses to influenza virus infection in mice.
    Arch Virol. 2021 Jun 10. pii: 10.1007/s00705-021-05112.
    PubMed     Abstract available
    
    
    
100. CHEN K, Kong M, Liu J, Jiao J, et al
     Rapid differential detection of subtype H1 and H3 swine influenza viruses using a TaqMan-MGB-based duplex one-step real-time RT-PCR assay.
     Arch Virol. 2021 Jun 6. pii: 10.1007/s00705-021-05127.
     PubMed     Abstract available
     
     
     
101. ROKIC F, Trgovec-Greif L, Sucic N, Cemeljic N, et al
     Diverse SARS-CoV-2 variants preceded the initial COVID-19 outbreak in Croatia.
     Arch Virol. 2021;166:1735-1739.
     PubMed     Abstract available
     
     
     
102. PEDREANEZ A, Mosquera-Sulbaran J, Munoz N
     SARS-CoV-2 infection represents a high risk for the elderly: analysis of pathogenesis.
     Arch Virol. 2021;166:1565-1574.
     PubMed     Abstract available
     
     
     May 2021
103. TANG Y, Yang G, Li Y, Wang M, et al
     Protective effects of SP600125 on mice infected with H1N1 influenza A virus.
     Arch Virol. 2021 May 20. pii: 10.1007/s00705-021-05103.
     PubMed     Abstract available
     
     
     
104. SOKOLOVA AS, Yarovaya OI, Baranova DV, Galochkina AV, et al
     Quaternary ammonium salts based on (-)-borneol as effective inhibitors of influenza virus.
     Arch Virol. 2021 May 13. pii: 10.1007/s00705-021-05102.
     PubMed     Abstract available
     
     
     
105. SYLVERKEN AA, El-Duah P, Owusu M, Schneider J, et al
     Transmission of SARS-CoV-2 in northern Ghana: insights from whole-genome sequencing.
     Arch Virol. 2021;166:1385-1393.
     PubMed     Abstract available
     
     
     April 2021
106. GONZALEZ-GARCIA LD, Martinez-Castillo M, Vargas-Pavia TA, Ulloa-Aguilar JM, et al
     Inhibition of AMP-activated protein kinase in respiratory syncytial virus infection activates lipid metabolism.
     Arch Virol. 2021;166:1177-1182.
     PubMed     Abstract available
     
     
     March 2021
107. ZINYAKOV NG, Sosipatorova VY, Andriyasov AV, Ovchinnikova EV, et al
     Genetic analysis of genotype G57 H9N2 avian influenza virus isolate A/chicken/Tajikistan/2379/2018 recovered in Central Asia.
     Arch Virol. 2021 Mar 19. pii: 10.1007/s00705-021-05011.
     PubMed     Abstract available
     
     
     
108. WOUK J, Rechenchoski DZ, Rodrigues BCD, Ribelato EV, et al
     Viral infections and their relationship to neurological disorders.
     Arch Virol. 2021;166:733-753.
     PubMed     Abstract available
     
     
     
109. DOWLATSHAHI S, Shabani E, Abdekhodaie MJ
     Serological assays and host antibody detection in coronavirus-related disease diagnosis.
     Arch Virol. 2021;166:715-731.
     PubMed     Abstract available
     
     
     
110. DABBOUS HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, et al
     Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
     Arch Virol. 2021;166:949-954.
     PubMed     Abstract available
     
     
     
111. VERMA J, Subbarao N
     A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics.
     Arch Virol. 2021;166:697-714.
     PubMed     Abstract available
     
     
     
112. SARKAR R, Mitra S, Chandra P, Saha P, et al
     Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: an endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations.
     Arch Virol. 2021;166:801-812.
     PubMed     Abstract available
     
     
     
113. HEMMAT N, Asadzadeh Z, Ahangar NK, Alemohammad H, et al
     The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV.
     Arch Virol. 2021;166:675-696.
     PubMed     Abstract available
     
     
     February 2021
114. YANG F, Xiao Y, Liu F, Yao H, et al
     Isolation and characterization of two novel reassortant H5N6 avian influenza viruses from waterfowl in eastern China.
     Arch Virol. 2021 Feb 17. pii: 10.1007/s00705-021-04995.
     PubMed     Abstract available
     
     
     
115. LI Y, Hu J, Lei J, Fan W, et al
     Development and application of a novel triplex protein microarray method for rapid detection of antibodies against avian influenza virus, Newcastle disease virus, and avian infectious bronchitis virus.
     Arch Virol. 2021 Feb 12. pii: 10.1007/s00705-021-04962.
     PubMed     Abstract available
     
     
     
116. TSUNEKI-TOKUNAGA A, Kanai K, Itagaki A, Tsuchie H, et al
     Growth capability of epidemic influenza viruses in Japan since the 2009 H1N1 pandemic.
     Arch Virol. 2021 Feb 12. pii: 10.1007/s00705-021-04976.
     PubMed     Abstract available
     
     
     January 2021
117. ALLKOFER A, Garvey M, Ryan E, Lyons R, et al
     Primary vaccination in foals: a comparison of the serological response to equine influenza and equine herpesvirus vaccines administered concurrently or 2 weeks apart.
     Arch Virol. 2021 Jan 7. pii: 10.1007/s00705-020-04846.
     PubMed     Abstract available
     
     
     
118. SABBAGHI A, Zargar M, Zolfaghari MR, Motamedi-Sedeh F, et al
     Protective cellular and mucosal immune responses following nasal administration of a whole gamma-irradiated influenza A (subtype H1N1) vaccine adjuvanted with interleukin-28B in a mouse model.
     Arch Virol. 2021 Jan 6. pii: 10.1007/s00705-020-04900.
     PubMed     Abstract available
     
     
     
119. NG KT, Takebe Y, Kamarulzaman A, Tee KK, et al
     Genome sequencing and phylogenetic reconstruction reveal a potential fourth rhinovirus species and its worldwide distribution.
     Arch Virol. 2021;166:225-229.
     PubMed     Abstract available
     
     
     
120. ARANCIO W
     ceRNA analysis of SARS-CoV-2.
     Arch Virol. 2021;166:271-274.
     PubMed     Abstract available
     
     
     
121. MOSQUERA-SULBARAN JA, Hernandez-Fonseca H
     Tetracycline and viruses: a possible treatment for COVID-19?
     Arch Virol. 2021;166:1-7.
     PubMed     Abstract available
     
     
     December 2020
122. REHMAN S, Mahmood T, Aziz E, Batool R, et al
     Identification of novel mutations in SARS-COV-2 isolates from Turkey.
     Arch Virol. 2020;165:2937-2944.
     PubMed     Abstract available
     
     
     November 2020
123. YANG X, Liang Y, Bamunuarachchi G, Xu Y, et al
     miR-29a is a negative regulator of influenza virus infection through targeting of the frizzled 5 receptor.
     Arch Virol. 2020 Nov 18. pii: 10.1007/s00705-020-04877.
     PubMed     Abstract available
     
     
     
124. LIU B, Wang Y, Liu Y, Chen Y, et al
     Molecular evolution and characterization of hemagglutinin and neuraminidase of influenza A(H1N1)pdm09 viruses isolated in Beijing, China, during the 2017-2018 and 2018-2019 influenza seasons.
     Arch Virol. 2020 Nov 3. pii: 10.1007/s00705-020-04869.
     PubMed     Abstract available
     
     
     
125. DADAR M, Fakhri Y, Bjorklund G, Shahali Y, et al
     The association between the incidence of COVID-19 and the distance from the virus epicenter in Iran.
     Arch Virol. 2020;165:2555-2560.
     PubMed     Abstract available
     
     
     
126. SHAMIM S, Khan M, Kharaba ZJ, Ijaz M, et al
     Potential strategies for combating COVID-19.
     Arch Virol. 2020;165:2419-2438.
     PubMed     Abstract available
     
     
     October 2020
127. GROHN S, Heinimaki S, Tamminen K, Blazevic V, et al
     Expression of influenza A virus-derived peptides on a rotavirus VP6-based delivery platform.
     Arch Virol. 2020 Oct 16. pii: 10.1007/s00705-020-04847.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: